BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
BioAtla (Nasdaq: BCAB), a clinical-stage biotechnology company, announced a poster presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting in Washington, DC, from December 13–15, 2024.
The presentation, titled Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC, will be delivered by a team of authors including Julia Rotow, Grace K. Dy, and others.
Details of the presentation include:
- Poster Number: PP01.03
- Session Type: Poster Reception
- Session Date and Time: Saturday, December 14, 2024, from 5:40 P.M. – 6:40 P.M. ET
Materials from the presentation will be available on the “Publication” section of BioAtla’s website after the event.
BioAtla (Nasdaq: BCAB), un'azienda biotecnologica in fase clinica, ha annunciato una presentazione di poster al IASLC 2024 Hot Topic in Basic & Translational Science Meeting che si terrà a Washington, DC, dal 13 al 15 dicembre 2024.
La presentazione, intitolata Caratterizzazione del Genotipo KRAS Mutato e Risultati Clinici in Pazienti con NSCLC Avanzato Trattati con Mecbotamab Vedotin, un CAB-AXL-ADC, sarà effettuata da un team di autori tra cui Julia Rotow, Grace K. Dy, e altri.
I dettagli della presentazione includono:
- Numero del Poster: PP01.03
- Tipo di Sessione: Ricezione dei Poster
- Data e Ora della Sessione: Sabato, 14 dicembre 2024, dalle 17:40 alle 18:40 ET
I materiali della presentazione saranno disponibili nella sezione
BioAtla (Nasdaq: BCAB), una empresa de biotecnología en etapa clínica, anunció una presentación de póster en la Reunión de Temas Candentes en Ciencia Básica y Traslacional del IASLC 2024 en Washington, DC, del 13 al 15 de diciembre de 2024.
La presentación, titulada Caracterización del Genotipo KRAS Mutado y Resultados Clínicos en Pacientes con NSCLC Avanzado Tratados con Mecbotamab Vedotin, un CAB-AXL-ADC, será realizada por un equipo de autores que incluye a Julia Rotow, Grace K. Dy, y otros.
Los detalles de la presentación incluyen:
- Número de Póster: PP01.03
- Tipo de Sesión: Recepción de Pósteres
- Fecha y Hora de la Sesión: Sábado, 14 de diciembre de 2024, de 5:40 P.M. a 6:40 P.M. ET
Los materiales de la presentación estarán disponibles en la sección de “Publicación” del sitio web de BioAtla después del evento.
BioAtla (Nasdaq: BCAB), 임상 단계의 생명공학 회사가 2024년 12월 13일부터 15일까지 워싱턴 D.C.에서 열리는 IASLC 2024 Hot Topic in Basic & Translational Science Meeting에서 포스터 발표를 진행한다고 발표했습니다.
이번 발표는 진행성 NSCLC 환자에서 Mecbotamab Vedotin, CAB-AXL-ADC로 치료한 변이 KRAS 유전자형 및 임상 결과의 특성화라는 제목으로, Julia Rotow, Grace K. Dy 등 저자 팀에 의해 진행될 것입니다.
발표에 대한 세부 사항은 다음과 같습니다:
- 포스터 번호: PP01.03
- 세션 유형: 포스터 리셉션
- 세션 날짜 및 시간: 2024년 12월 14일 토요일, 오후 5:40 – 6:40 ET
발표 자료는 행사 후 BioAtla 웹사이트의 “출판” 섹션에서 확인할 수 있습니다.
BioAtla (Nasdaq: BCAB), une entreprise de biotechnologie en phase clinique, a annoncé une présentation d'affiche lors de l'IASLC 2024 Hot Topic in Basic & Translational Science Meeting à Washington, DC, du 13 au 15 décembre 2024.
La présentation, intitulée Caractérisation du génotype KRAS muté et des résultats cliniques chez les patients atteints de NSCLC avancé traités avec Mecbotamab Vedotin, un CAB-AXL-ADC, sera délivrée par une équipe d'auteurs comprenant Julia Rotow, Grace K. Dy et d'autres.
Les détails de la présentation comprennent :
- Numéro de l'affiche : PP01.03
- Type de session : Réception des affiches
- Date et heure de la session : Samedi 14 décembre 2024, de 17h40 à 18h40 ET
Les documents de la présentation seront disponibles dans la section « Publications » du site Web de BioAtla après l'événement.
BioAtla (Nasdaq: BCAB), ein biotechnologisches Unternehmen in der klinischen Phase, hat eine Posterpräsentation auf der IASLC 2024 Hot Topic in Basic & Translational Science Meeting in Washington, DC, vom 13. bis 15. Dezember 2024 angekündigt.
Die Präsentation mit dem Titel Charakterisierung des mutierten KRAS-Genotyps und klinische Ergebnisse bei Patienten mit fortgeschrittenem NSCLC, die mit Mecbotamab Vedotin, einem CAB-AXL-ADC, behandelt wurden, wird von einem Autorenteam, darunter Julia Rotow, Grace K. Dy und andere, durchgeführt.
Die Einzelheiten zur Präsentation umfassen:
- Poster-Nummer: PP01.03
- Session-Typ: Posterempfang
- Session-Datum und -Zeit: Samstag, 14. Dezember 2024, von 17:40 bis 18:40 Uhr ET
Materialien aus der Präsentation werden nach der Veranstaltung im Bereich „Veröffentlichung“ der BioAtla-Website verfügbar sein.
- BioAtla's participation in the IASLC 2024 meeting highlights the company's ongoing research and development efforts.
- The presentation on Mecbotamab Vedotin may provide valuable insights into the treatment of advanced NSCLC, potentially boosting investor confidence.
- None.
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 Hot Topic in Basic & Translational Science Meeting to be held in Washington, DC from December 13–15, 2024.
Presentation Details:
| Title: | Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC | |
| Authors: | Julia Rotow, Grace K. Dy, Edwin Yau, Elaine Shum, Mariam Alexander, Karen L. Reckamp, Roland Leung, Dariusz M. Kowalski, Jose Fuentes Pradera, Jon Zugazagoitia Fraile, Kyechin Chen, Kartik Aysola, D. Ross Camidge | |
| Poster Number: | PP01.03 | |
| Session Type: | Poster Reception | |
| Session Date and Time: | Saturday, December 14, 2024 from 5:40 P.M. – 6:40 P.M. ET |
A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentation has concluded.
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. To learn more about BioAtla, Inc. visit www.bioatla.com.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
What event will BioAtla present at?
When and where is the IASLC 2024 meeting?
What is the focus of BioAtla's presentation at the IASLC 2024 meeting?
When will BioAtla's poster presentation take place?
Where can the presentation materials be accessed?
